natgillin/translations-raw huggingface dataset:
In adults 18 to 64 years of age, the most frequently reported adverse reactions after vaccination were injection site pain (80.5%), muscle aches (37.2%), fatigue (25.2%), headache (25.1%), joint pain (17.7%) and shivering (11.1%).
U odraslih osoba od 18 do 64 godina najčešće prijavljene nuspojave nakon cijepljenja bile su: bol na mjestu injiciranja (80,5%), bolovi u mišićima (37,2%), umor (25,2%), glavobolja (25,1%), bol u zglobovima (17,7%) i drhtanje (11,1%).
In adults aged 18-49 years, OPA GMTs to all 13 serotypes in Prevenar 13 were non-inferior to the Prevenar 13 responses in adults aged 60-64 years.
U odraslih osoba u dobi od 18 do 49 godina, geometrijske sredine OPA titara na svih 13 serotipova u Prevenaru 13 su bile neinferiorne odgovoru na Prevenar 13 u odraslih osoba u dobi od 60 do 64 godine.
In adults aged 50 and older, in the first two main studies Prevenar 13 produced an immune response that was at least as good as the 23-valent polysaccharide vaccine for all 12 of the S. pneumoniae polysaccharides they share in common, and for several of these serotypes the immune response was better with Prevenar 13.
U odraslih osoba u dobi od 50 godina i starijih, u prva dva glavna ispitivanja Prevenar 13 prouzročio je imunološki odgovor koji je bio najmanje podjednako dobar kao 23-valentno polisaharidno cjepivo za svih 12 pneumokoknih polisaharida koji su im zajednički, a za nekoliko ovih serotipa imunološki je odgovor bio bolji s lijekom Prevenar 13.
In adults and adolescents aged 11 and over, two injections are given (at an interval of at least one month).
Odraslim osobama i adolescentima u dobi od 11 godina i starijima daju se dvije injekcije (u intervalu od najmanje mjesec dana).
In adults and adolescents aged 16 years and over, the recommended starting dose is 1,500 mg per square metre of body surface area (calculated using the patient's height and weight),
U odraslih osoba i adolescenata u dobi od 16 godina i starijih, preporuče se početna doza od 1.500 mg po metru kvadratnom tjelesne površine (izračunato uz primjenu visine i tjelesne težine bolesnika), primjenjujući
In adults and adolescents from 12 to 18 years of age and weighing at least 33 kilograms, the recommended dose is 600 mg every 12 hours.
U odraslih osoba i adolescenata od 12 do 18 godina čija je tjelesna težina najmanje 33 kilograma preporučena je doza 600 mg svakih 12 sati.
in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis (see section 4.4).
u odraslih i djece u dobi od 1 do 18 godina na hemodijalizi te odraslih bolesnika na peritonealnoj dijalizi (vidjeti dio 4.4).
In adults it also prevents this condition from returning in patients who have responded to the treatment with ABILIFY oral solution.
ABILIFY oralna otopina također sprječava povratak takvog stanja u odraslih bolesnika koji su prethodno imali odgovor na terapiju ABILIFY oralnom otopinom.
In adults it also prevents this condition from returning in patients who have responded to the treatment with ABILIFY orodispersible tablets.
ABILIFY raspadljive tablete za usta također sprječavaju povratak takvog stanja u odraslih bolesnika koji su prethodno imali odgovor na terapiju ABILIFY raspadljivim tabletama za usta.
In adults it also prevents this condition from returning in patients who have responded to the treatment with ABILIFY tablets.
ABILIFY također sprječava povratak takvog stanja u odraslih bolesnika koji su prethodno imali odgovor na liječenje ABILIFY tabletama.
In adults it also prevents this condition from returning in patients who have responded to the treatment with Aripiprazole Mylan Pharma tablets.
Aripiprazole Mylan Pharma također sprječava povratak takvog stanja u odraslih bolesnika koji su prethodno imali odgovor na liječenje Aripiprazole Mylan Pharma tabletama.
In adults it also prevents this condition from returning in patients who have responded to the treatment with Aripiprazole Sandoz tablets.
Aripiprazol Sandoz tablete također sprječavaju povratak takvog stanja u odraslih bolesnika koji su prethodno imali odgovor na terapiju lijekom Aripiprazol Sandoz tablete.
In adults it is used if you have a fast, irregular heart beat called atrial fibrillation which has started recently (less than or equivalent to 7 days) for non-surgery patients and less than or equivalent to 3 days for post-cardiac surgery patients.
Primjenjuje se u odraslih bolesnika ako imaju ubrzan, nepravilan rad srca koji se zove fibrilacija atrija, koja se u bolesnika koji nisu operirani pojavila nedavno (prije 7 dana ili manje), a u bolesnika nakon operacije srca prije 3 dana ili manje.
In adults it is usually given as 180 micrograms once a week for 48 weeks, although some hepatitis C
Kod odraslih se obično daje u obliku 180 mikrograma jednom tjedno tijekom 48 tjedana, iako nekim bolesnicima s hepatitisom C može biti potrebno 16, 24 ili 72
In adults Omnitrope is used to treat persons with pronounced growth hormone deficiency.
Omnitrope se u odraslih koristi za: liječenje osoba s izraženim nedostatkom hormona rasta.
in adults on haemodialysis or peritoneal dialysis in severely anaemic adults not yet undergoing dialysis
u odraslih na hemodijalizi ili peritonealnoj dijalizi u odraslih s teškom anemijom koji još nisu započeli dijalizu
In adults taking ribavirin and an alpha interferon:
Kod odraslih osoba koje uzimaju ribavirin i interferon alfa:
In adults the dose should be reduced from 400 to 300 mg or from 600 to 400 mg, or from 800 mg to 600 mg, and in children from 340 to 260 mg/m2/day.
Dozu u odraslih treba sniziti s400 na 300 mg ili s 600 na 400 mg, ili s 800 mg na 600 mg,a u djece s 340 na 260 mg/m2/dan.
In adults the total clearance adjusted for bioavailability was 9.89 l/h (0.16 l/h/kg) thereof 5.64 and 4.25 l/h by renal and non-renal clearance, respectively.
Kod odraslih bolesnika ukupni klirens prilagođen prema bioraspoloživosti bio je 9,89 l/h (0,16 l/h/kg) od čega se 5,64 l/h odnosilo na renalni klirens, a 4,25 l/h na nerenalni klirens.
in adults unable to tolerate or with a contra-indication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal beta- blocker dose.
u odraslih bolesnika koji ne podnose beta-blokatore ili je njihova primjena kontraindicirana ili u kombinaciji s beta blokatorima u bolesnika koji nisu adekvatno kontrolirani s optimalnom dozom beta blokatora.
In adults vaccinated with pneumococcal polysaccharide vaccine at least 5 years prior to the clinical study, OPA GMTs to Prevenar 13 were non-inferior to the 23-valent pneumococcal polysaccharide vaccine responses for the 12 serotypes in common.
U odraslih cijepljenih pneumokoknim polisaharidnim cjepivom najmanje 5 godina prije kliničkog ispitivanja, geometrijske sredine OPA titara na Prevenar 13 bile se neinferiorne odgovorima na 23- valentno pneumokokno polisaharidno cjepivo za 12 zajedničkih serotipova.
In adults vaccinated with pneumococcal polysaccharide vaccine at least 5 years prior to the clinical study, OPA GMTs to Prevenar 13 were non-inferior to the 23-valent pneumococcal polysaccharide vaccine responses for the 12 serotypes in common.
U odraslih cijepljenih pneumokoknim polisaharidnim cjepivom najmanje 5 godina prije kliničkog ispitivanja, geometrijske sredine OPA titara na Prevenar 13 bile su neinferiorne odgovorima na 23- valentno pneumokokno polisaharidno cjepivo za 12 zajedničkih serotipova.
In adults with chronic hepatitis B and compensated liver disease, Viread was more effective than adefovir dipivoxil.
U odraslih osoba s kroničnim hepatitisom B i kompenziranom bolešću jetre, Viread je bio učinkovitiji od adefovirdipivoksila.
In adults with leukaemia, the initial enzymatic activity after intravenous adminstration of Oncaspar was proportional to the dose.
Kod odraslih osoba s leukemijom početna enzimska aktivnost nakon intravenske primjene Oncaspara bila je proporcionalna dozi.
in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients (see section 4.4).
u odraslih s insuficijencijom bubrega koji još nisu na dijalizi za liječenje teške anemije bubrežnog porijekla praćene kliničkim simptomima u bolesnika (vidjeti dio 4.4).
In adults with severe aplastic anaemia the most common side effects included headache, dizziness, insomnia, cough, dyspnoea (difficulty breathing), pain in the tummy or in the mouth and throat, nausea, diarrhoea, joint pain, muscle spasms, pain in limbs, fatigue, fever, ecchymosis (discoloration of the skin resulting from bleeding underneath), abnormal blood levels of certain liver enzymes and runny nose.
Kod bolesnika s teškom aplastičnom anemijom najčešće nuspojave su među ostalim bile glavobolja, vrtoglavica, nesanica, kašalj, dispneja (poteškoće pri disanju), bol u trbuhu ili ustima i grlu, mučnina, proljev, bol u zglobovima, grčevi mišića, bol u udovima, iscrpljenost, vrućica, ekhimoza (gubitak boje kože kao posljedica krvarenja ispod kože), abnormalne razine nekih enzima jetre i hunjavica.
In adults with Sickle Cell Syndrome, mean cumulative urinary hydroxycarbamide excretion was 62% of the administered dose at 8 hours, and thus higher than in cancer patients (35–40%).
Kod odraslih sa sindromom srpastih stanica srednja vrijednost kumulativnog izlučivanja hidroksikarbamida putem urina iznosila je 62% primijenjene doze tijekom 8 sati, što je više nego kod bolesnika koji boluju od raka (35-40%).
In adults with thrombocytopenia associated with hepatitis C, the recommended starting dose is 25 mg once a day in patients of all ethnicities.
U odraslih bolesnika s trombocitopenijom koja je povezana s hepatitisom C preporučena početna doza iznosi 25 mg jednom dnevno za sve bolesnike bez obzira na njihovu etničku pripadnost.
In adults, a second dose may be given within 30 minutes of the first injection.
Kod odraslih, može se primijeniti druga doza unutar 30 min nakon prve injekcije.
In adults, adolescents and children older than 2 years
Odrasli, adolescenti i djeca starija od 2 godine
in adults, children and adolescents on haemodialysis to treat symptomatic anaemia (low red blood cell counts) associated with chronic renal failure (kidney disease).
kod odraslih, djece i adolescenata na hemodijalizi za liječenje simptomatske anemije (smanjen broj crvenih krvnih stanica) povezane s kroničnim zatajenjem bubrega (bubrežna bolest).
In adults, Cubicin is given by intravenous infusion (see section 6.6) and administered over a 30- minute period or by intravenous injection (see section 6.6) and administered over a 2-minute period.
U odraslih, Cubicin se daje intravenskom infuzijom (vidjeti dio 6.6) koja se primjenjuje u trajanju od 30 minuta ili intravenskom injekcijom (vidjeti dio 6.6) koja se primjenjuje u trajanju od 2 minute.
In adults, Cubicin is given into a vein by a doctor or a nurse as an infusion lasting 30 minutes or as an injection lasting two minutes.
U odraslih osoba liječnik ili medicinska sestra daje Cubicin u venu u obliku infuzije u trajanju od 30 minuta ili injekcije koja traje dvije minute.
In adults, different dose levels are indicated in column title. d Vss is reported for paediatric cancer patients, whereas Vz is reported for adult cancer patients.
Za odrasle bolesnike različite razine doza naznačene su u naslovima stupaca. d Volumen distribucije u stanju dinamičke ravnoteže (Vss) naveden je za pedijatrijske bolesnike s karcinomom, a konačni volumen distribucije (Vz) za odrasle bolesnike s karcinomom.
In adults, Edurant in combination with other antiretroviral medicines was as effective as the comparator medicine at reducing the level of HIV-1 in the patients’ blood.
U odraslih osoba, Edurant je, ako se uzimao u kombinaciji s drugim protuvirusnim lijekovima, bio jednako učinkovit kao i usporedni lijek u snižavanju razine virusa HIV-1 u krvi bolesnika.
In adults, including those aged above 65 years, and children aged three years and older, a full dose of Ixiaro (0.5 ml) should be given, and an additional 0.5 ml dose should be given four weeks later.
U odraslih osoba, uključujući one starije od 65 godina, te djece u dobi od 3 godine i starije treba primijeniti potpunu dozu lijeka Ixiaro (0,5 ml), a dodatnu dozu od 0,5 ml treba primijeniti četiri tjedana kasnije.
In adults, it can also be used for those patients with liver damage whose liver is not working properly (decompensated liver disease) and those patients who do not respond to treatment with lamivudine (another HIV medicine).
U odraslih osoba ovaj se lijek može primjenjivati u bolesnika s oštećenjem funkcije jetre čija jetra ne funkcionira normalno (dekompenzirana bolest jetre) i u bolesnika koji ne odgovaraju na liječenje lamivudinom (drugi lijek protiv HIV-a).
In adults, it should be started at a dose of 62.5 mg twice a day for four weeks and then increased to the usual dose of 125 mg twice a day.
Terapiju u odraslih osoba treba započeti s dozom od 62,5 mg dva puta na dan tijekom četiri tjedana te zatim povećati na uobičajenu dozu od 125 mg dva puta na dan.
In adults, Ixiaro (given as two doses 4 weeks apart) was as effective as the comparator vaccine at triggering the production of antibodies against the Japanese encephalitis virus.
U odraslih osoba lijek Ixiaro (primijenjen u dvije doze u razmaku od 4 tjedna) bio je jednako djelotvoran kao i usporedno cjepivo pri aktiviranju stvaranja protutijela protiv virusa japanskog encefalitisa.
In adults, Ketek is used to treat infections of the throat, infections of the sinuses (hollow cavities in the bones around the nose) and chest infections in patients with long standing breathing difficulties and lung infection (pneumonia).
U odraslih se Ketek koristi za liječenje infekcija grla, infekcija sinusa (šupljina u kostima oko nosa), infekcija dišnog sustava u bolesnika koji imaju dugotrajne poteškoće s disanjem te infekcija pluća (upale pluća).
In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1,000 mg, 2,000 mg, or 3,000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks.
Djelotvornost levetiracetama dokazana je u odraslih u 3 dvostruko slijepa i placebom kontrolirana ispitivanja gdje su bolesnici tijekom liječenja 18 tjedana dobivali 1000 mg, 2000 mg ili 3000 mg/dan, podjeljeno na dvije doze.
In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks.
Djelotvornost levetiracetama dokazana je u odraslih u 3 dvostruko-slijepe i placebom kontrolirane studije gdje su bolesnici tokom liječenja 18 tjedana dobivali 1000 mg, 2000 mg ili 3000 mg/dan, podjeljeno na dvije doze.
In adults, NutropinAq is used:
Kod odraslih se NutropinAq koristi:
In adults, the most common side effects when taking Abilify by mouth (seen in between 1 and 10 patients in 100) are restlessness, insomnia (difficulty sleeping), anxiety, extrapyramidal disorder (uncontrolled twitching or jerking), akathisia (a constant urge to move), tremor (shaking), dizziness, somnolence (sleepiness), sedation (drowsiness), headache, blurred vision, dyspepsia (heartburn), vomiting, nausea (feeling sick), constipation, salivary hypersecretion (increased production of saliva) and fatigue (tiredness).
Kod odraslih osoba najčešće nuspojave prilikom peroralnog uzimanja lijeka (uočene između 1 i 10 bolesnika na 100) bile su nemir, nesanica (poteškoće u spavanju), tjeskoba, ekstrapiramidalni poremećaj (nekontrolirano trzanje i grčenje), akatizija (stalna potreba za kretanjem), tremor (tresavica), vrtoglavica, somnolencija (pospanost), sedacija (omamljenost), glavobolja, zamućeni vid, dispepsija (žgaravica), povraćanje, mučnina, zatvor stolice, salivarna hipersekrecija (prekomjerno izlučivanje sline) i zamor (umor).
In adults, the most common side effects with Prezista are diarrhoea, ‘immune reconstitution syndrome’, nausea (feeling sick), pyrexia (fever) and rash.
Kod odraslih osoba, najčešće nuspojave s lijekom Prezista su proljev, „sindrom imunosne rekonstitucije”, mučnina, pireksija (vrućica) i osip.
In adults, the recommended dose of Intelence is 200 mg (as two 100 mg tablets or one 200 mg tablet) twice a day after a meal.
U odraslih osoba preporučena doza lijeka Intelence iznosi 200 mg (primjenjuje se kao dvije tablete od 100 mg ili jedna tableta od 200 mg) dva puta na dan nakon obroka.
In adults, the second dose can be given up to 11 months after the first.
U odraslih osoba druga se doza može dati do 11 mjeseci nakon prve doze.
In adults, treatment begins with a 70- mg starting dose, followed by a daily dose of 50 mg, or of 70 mg if the patient weighs more than 80 kg.
U odraslih, liječenje počinje početnom dozom od 70 mg, a nastavlja se dnevnom dozom od 50 mg ili 70 mg ako bolesnik ima više od 80 kg.
In adults, treatment starts with a 70 mg on the first day, followed by a daily dose of 50 mg, or 70 mg if the patient weighs more than 80 kg.
U odraslih, liječenje se započinje početnom dozom od 70 mg prvog dana, a nastavlja se dnevnom dozom od 50 mg ili 70 mg ako bolesnik ima više od 80 kg.
In ADVANCE MPI 1 and ADVANCE MPI 2, the Cicchetti-Allison and Fleiss-Cohen weighted kappas of the median score of three blinded readers with respect to ischaemia size category (not counting segments with normal rest uptake and mild/equivocal reduction in stress uptake as ischaemic) for the combined studies of regadenoson with the adenosine scan were moderate, 0.53 and 0.61, respectively; as were the weighted kappas of two consecutive adenosine scans, 0.50 and 0.55, respectively.
U ispitivanjima ADVANCE MPI 1 i ADVANCE MPI 2, Cicchetti-Allisonov i Fleiss-Cohenov ponderirani kapa koeficijent za medijan rezultata tri slijepa čitača, uzimajući u obzir kategoriju veličine ishemije (ne računajući pritom segmente s normalnom apsorpcijom radionuklida u mirovanju, a s blagom/nejasnom redukcijom preuzimanja radionuklida u naporu kao ishemičke), u kombiniranom ispitivanju snimaka učinjenih primjenom regadenosona i adenozina bili su umjereni (0,53 odnosno 0,61); jednako tako bili su ponderirani kapa koeficijenti za dvije uzastopne snimke učinjene primjenom adenozina, 0,50 odnosno 0,55.
In ADVANCE MPI 1 and ADVANCE MPI 2, the following pre-specified safety and tolerability endpoints comparing Rapiscan to adenosine achieved statistical significance: (1) a summed score of both the presence and severity of the symptom groups of flushing, chest pain, and dyspnoea was lower with Rapiscan (0.9 ± 0.03) than with adenosine (1.3 ± 0.05); and (2) the symptom groups of flushing (21% vs 32%), chest pain (28% vs 40%), and ‘throat, neck or jaw pain’ (7% vs 13%) were less frequent with Rapiscan; the incidence of headache (25% vs 16%) was more frequent with Rapiscan.
U ispitivanjima ADVANCE MPI 1 i ADVANCE MPI 2 sljedeći su prespecificirani krajnji ishodi sigurnosti i podnošljivosti bili statistički značajni u usporedbi Rapiscana s adenozinom: (1) zbirni rezultat za prisutnost i težina simptoma u skupinama sa simptomima crvenila s osjećajem vrućine, bolova u prsnom košu i dispneje bili si niži za Rapiscan (0,9 ± 0,03) nego za adenozin (1,3 ± 0,05); i (2) u skupinama sa simptomima crvenila (21% odnosno 32%), bolova u prsnom košu (28% odnosno 40%), i ‘boli u grlu, vratu i čeljusti’ (7% odnosno 13%) bili su manje česti za Rapiscan; incidencija glavobolje (25% odnosno 16%) bila je češća za Rapiscan.
In advanced gastric cancer, Xeloda with cisplatin has been compared with a combination of 5-FU and cisplatin in one study involving 316 patients.
U slučaju uznapredovalog gastričnog karcinoma, lijek Xeloda s cisplatinom bio je uspoređen s kombinacijom 5-FU-a i cisplatina u jednom ispitivanju kojim je obuhvaćeno 316 bolesnika.
In advanced gastric cancer, Xeloda with cisplatin was as effective as 5-FU and cisplatin.
U slučaju uznapredovalog gastričnog raka, lijek Xeloda s cisplatinom bio je jednako djelotvoran kao 5- FU i cisplatin.
In advanced or metastatic kidney cancer, Avastin has been studied in 649 patients with advanced or metastatic disease.
U slučaju uznapredovalog ili metastatskog raka bubrega, Avastin je ispitivan u 649 bolesnika oboljelih od uznapredovale ili metastatske bolesti.
In advanced or metastatic kidney cancer, the average progression-free survival was 10.2 months in the patients receiving Avastin and 5.4 months in those receiving placebo.
U slučaju uznapredovalog ili metastatskog raka bubrega, prosječno razdoblje preživljenja bez progresije iznosilo je 10,2 mjeseci u bolesnika koji su primali lijek Avastin i 5,4 mjeseca u bolesnika koji su primali placebo.
In advanced Parkinson’s disease, doses higher than 1.1 mg (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended.
U uznapredovaloj Parkinsonovoj bolesti, dnevne doze više od 1,1 mg baze (1,5 mg soli) mogu biti korisne u bolesnika kojima se namjerava sniziti terapija levodope.
In advanced Parkinson’s disease, in combination treatment with levodopa, dyskinesia can occur during the initial titration of MIRAPEXIN.
Tijekom početne titracije MIRAPEXINA kod uznapredovale Parkinsonove bolesti, može doći do pojava diskinezije kod bolesnika liječenih kombinacijom pramipeksola i levodope.
In advanced Parkinson’s disease, in combination treatment with levodopa, dyskinesia can occur during the initial titration of Oprymea.
Tijekom početne titracije lijeka Oprymea kod uznapredovale Parkinsonove bolesti, može doći do pojava diskinezije u bolesnika liječenih kombinacijom pramipeksola i levodope.
In advanced Parkinson’s disease, in combination treatment with levodopa, dyskinesia can occur during the initial titration of Pramipexole Accord.
Tijekom početne titracije Pramipeksol Accorda kod uznapredovale Parkinsonove bolesti, može doći do pojava diskinezije kod bolesnika liječenih kombinacijom pramipeksola i levodope.
In advanced Parkinson’s disease, in combination treatment with levodopa, dyskinesia can occur during the initial titration of Pramipexole Teva.
Tijekom početne titracije lijeka Pramipeksol Teva kod uznapredovale Parkinsonove bolesti, može doći do pojava diskinezije kod bolesnika liječenih kombinacijom pramipeksola i levodope.
In advanced Parkinson’s disease, in combination treatment with levodopa, dyskinesia can occur during the initial titration of SIFROL.
Tijekom početne titracije SIFROLA kod uznapredovale Parkinsonove bolesti, može doći do pojava diskinezije kod bolesnika liječenih kombinacijom pramipeksola i levodope.
In advanced Parkinson’s disease, in combination treatment with levodopa, dyskinesias can occur during the initial titration of Oprymea.
Tijekom početne titracije lijeka Oprymea kod uznapredovale Parkinsonove bolesti, može doći do pojava diskinezije u bolesnika liječenih kombinacijom pramipeksola i levodope.
In advanced Parkinson’s disease, pramipexole doses higher than 1.05 mg of base (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended.
U uznapredovaloj Parkinsonovoj bolesti, dnevne doze pramipeksola više od 1,05 mg baze (1,5 mg soli) mogu biti korisne u bolesnika kojima se namjerava sniziti doza levodope.
In advanced Parkinson’s disease, pramipexole doses higher than 1.05 mg of base (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended.
U uznapredovaloj Parkinsonovoj bolesti, dnevne doze više od 1,05 mg baze (1,5 mg soli) mogu biti korisne kod bolesnika kojima se namjerava sniziti doza levodope.
In advanced Parkinson’s disease, pramipexole doses higher than 1.1 mg of base (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended.
U uznapredovaloj Parkinsonovoj bolesti, dnevne doze pramipeksola više od 1,1 mg baze (1,5 mg soli) mogu biti korisne kod bolesnika kojima se namjerava sniziti terapija levodope.
In advanced Parkinson’s disease, pramipexole doses higher than 1.1 mg of base (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended.
U uznapredovaloj Parkinsonovoj bolesti, dnevne doze više od 1,1 mg baze (1,5 mg soli) mogu biti korisne kod bolesnika kojima se namjerava sniziti doza levodope.